Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-02-01 Epub Date: 2024-11-29 DOI:10.1080/14796694.2024.2433412

Ashton Hunt, Daria Ditri, Ankit Chadha, Georgina Keogh, Jack Thompson, Will Loughborough, Iain McNeish, Jonathan Krell, Jacqueline McDermott, Laura Tookman, Sadaf Ghaem-Maghami

{"title":"Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.","authors":"Ashton Hunt, Daria Ditri, Ankit Chadha, Georgina Keogh, Jack Thompson, Will Loughborough, Iain McNeish, Jonathan Krell, Jacqueline McDermott, Laura Tookman, Sadaf Ghaem-Maghami","doi":"10.1080/14796694.2024.2433412","DOIUrl":null,"url":null,"abstract":"Introduction: Testing for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients.Methods: HRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023.Results: A total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% (n = 40/60), at primary surgery 91.5% (n = 42/47), and at interval debulking surgery 51.2% (n = 21/41). The use of a larger 16-gauge needle used at image-guided biopsy produced a 100% success rate. Of 148 tests carried out, the median time for result was 28 days (range 14-158 days), with only 27% returned results in 21 or fewer days. In successful tests, 44.7% were classified as HRD-positive. 97% of patients with HRD-positive tumors treated at the center received a PARP inhibitor as part of their first-line maintenance treatment.Conclusions: By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"341-347"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792859/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2433412","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Testing for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients.

Methods: HRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023.

Results: A total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% (n = 40/60), at primary surgery 91.5% (n = 42/47), and at interval debulking surgery 51.2% (n = 21/41). The use of a larger 16-gauge needle used at image-guided biopsy produced a 100% success rate. Of 148 tests carried out, the median time for result was 28 days (range 14-158 days), with only 27% returned results in 21 or fewer days. In successful tests, 44.7% were classified as HRD-positive. 97% of patients with HRD-positive tumors treated at the center received a PARP inhibitor as part of their first-line maintenance treatment.

Conclusions: By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.

查看原文本刊更多论文

高级别卵巢癌患者同源重组缺陷检测：影响检测成功的因素。

推荐所有晚期高级别上皮性卵巢癌患者进行肿瘤BRCA突变和同源重组缺陷（HRD）检测。HRD检测过程的延误会严重影响向患者提供的治疗。方法：分析2020年12月至2023年1月从三级妇科肿瘤转诊中心发送的HRD检测途径和抽样过程。结果：125例患者共进行148次hRD检查。HRD检测总成功率为69.6%。诊断性影像引导活检获得结果的成功率分别为66.7% （n = 40/60）、91.5% （n = 42/47）和51.2% （n = 21/41）。使用较大的16号针头进行图像引导活检的成功率为100%。在进行的148次测试中，获得结果的中位时间为28天（范围14-158天），只有27%的人在21天或更短的时间内返回结果。在成功的测试中，44.7%的人被归类为hrd阳性。在该中心接受治疗的97%的hrd阳性肿瘤患者接受了PARP抑制剂作为一线维持治疗的一部分。结论：通过优化影响HRD检测成功的因素，可以更快地获得结果，在更早的时间点为患者提供合适的治疗，从而改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.